Pharsight

Exservan patents expiration

EXSERVAN's oppositions filed in EPO
EXSERVAN IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8765167 AQUESTIVE Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
Feb, 2024

(3 months ago)

US8603514 AQUESTIVE Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
Apr, 2024

(2 months ago)

Exservan is owned by Aquestive.

Exservan contains Riluzole.

Exservan has a total of 2 drug patents out of which 2 drug patents have expired.

Expired drug patents of Exservan are:

  • US8765167
  • US8603514

Exservan was authorised for market use on 22 November, 2019.

Exservan is available in film;oral dosage forms.

The generics of Exservan are possible to be released after 03 April, 2024.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using RILUZOLE ingredient

Market Authorisation Date: 22 November, 2019

Treatment: NA

Dosage: FILM;ORAL

More Information on Dosage

EXSERVAN family patents

Family Patents